Podium Presentation to Highlight Efficacy, Cardiovascular Safety, Sleep Quality, and Quality of Life in Patients Receiving Low-Dose Fenfluramine for the Treatment of Dravet Syndrome
EMERYVILLE, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that new data on ZX008 (low-dose fenfluramine) will be presented at the 14thInternational Child Neurology Congress (ICNC), which will take place in Amsterdam, The Netherlands, from May 1 – 5, 2016. The presentation will report the latest efficacy and safety data from the prospectively followed cohort of patients treated with ZX008 for Dravet syndrome, a rare and catastrophic form of childhood epilepsy. In addition, for the first time, data will be presented on patient and caregiver sleep quality and quality of life.
Zogenix is currently conducting a Phase 3 clinical study evaluating ZX008 as an adjunctive treatment of seizures in children with Dravet syndrome. ZX008 is designated as an orphan drug in both the U.S. and Europe and recently received Fast Track designation in the U.S. for the treatment of Dravet syndrome.
Details of the presentation are below.
ICNC – May 1-5, 2016, Amsterdam, The Netherlands
Title: Low-dose Add-on Fenfluramine in Dravet Syndrome: Effect on Seizure Control, Sleep Quality, and Quality of Life in a Prospective Open-label Study
Date: May 5, 2016
Session Title: Epilepsy - Treatment and outcome 2
About the ZX008 Phase 3 Program
The Zogenix study entitled, "A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome," is being conducted for patients with Dravet syndrome whose seizures are not adequately controlled on their current medication. For more information, please visit www.clinicaltrials.gov listing (NCT02682927).
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com